4 completed, 3 terminated. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Steven E. Coutre: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Ibrutinib, Venetoclax - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Completed | Steven E. Coutre | 22 | 2017-09-26 | 2021-09-29 |
| Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Ibrutinib, Idarubicin - Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Terminated | Steven E. Coutre | 2 | 2016-11-01 | 2018-05-14 |
| Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Ixazomib - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Terminated | Steven E. Coutre | 4 | 2014-03-01 | 2019-04-05 |
| Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) Temozolomide, Vorinostat - Acute Myeloid Leukemia With 11q23-abnormality in Relapse | Phase 2 | Completed | Steven E. Coutre | 23 | 2013-05-01 | 2018-08-09 |
| Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia MAb 216, Vincristine - Leukemia, Lymphocytic, Leukemia | Phase 1 | Completed | Steven E. Coutre | 9 | 2006-05-01 | 2012-07-03 |
| Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia Alemtuzumab, Fludarabine, Cytoxan - Leukemia, B-cell Leukemia | Phase 2 | Completed | Steven E. Coutre | 25 | 2004-07-01 | 2014-10-06 |
| Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Gleevec - Eosinophilia, Hypereosinophilic Syndrome | Phase 2 | Terminated | Steven E. Coutre | 5 | 2003-06-12 | 2021-05-10 |
Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Congenital Abnormalities (1) · Eosinophilia (1) · Hypereosinophilic Syndrome (1) · Leukemia, B-Cell (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Lymphoid (1) · Leukemia, Megakaryoblastic, Acute (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myelomonocytic, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
ibrutinib (2) · Alemtuzumab (1) · Cyclophosphamide (1) · Cytarabine (1) · Idarubicin (1) · Imatinib Mesylate (1) · Proteasome Inhibitors (1) · Temozolomide (1) · Vincristine (1) · Vorinostat (1) · fludarabine (1) · fludarabine phosphate (1) · ixazomib (1) · venetoclax (1)
United States (7)
Steven Coutre (2) · Bruno de Medeiros (1) · Nelson N Teng (1) · Steven E Coutre (1) · Steven E Coutre, MD (1) · Steven Edward Coutre (1)
P30CA124435 (2)